Advanced Enzyme Technologies Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Advanced Enzyme Technologies yıllık ortalama 3.8% oranında kazançlarını artırırken, Chemicals sektöründe kazançlar growing at 6.7% annual. Gelirler growing yılda ortalama 7.7% oranında artmaktadır. Advanced Enzyme Technologies'in özkaynak karlılığı 10.3% ve net marjı 21.6%'dir.
Anahtar bilgiler
3.81%
Kazanç büyüme oranı
3.78%
EPS büyüme oranı
| Chemicals Sektör Büyümesi | 17.68% |
| Gelir büyüme oranı | 7.68% |
| Özkaynak getirisi | 10.31% |
| Net Marj | 21.61% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.Anlatı Güncellemesi • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.Anlatı Güncellemesi • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.Anlatı Güncellemesi • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.Anlatı Güncellemesi • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.Anlatı Güncellemesi • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analiz Makalesi • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Yeni Anlatı • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Analiz Makalesi • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analiz Makalesi • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analiz Makalesi • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analiz Makalesi • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...Analiz Makalesi • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Analiz Makalesi • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Analiz Makalesi • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analiz Makalesi • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analiz Makalesi • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Analiz Makalesi • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analiz Makalesi • May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Analiz Makalesi • Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Analiz Makalesi • Mar 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...Analiz Makalesi • Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
We note that a Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) insider, Madhusudan Soni, recently sold ₹5.7m...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Advanced Enzyme Technologies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 7,806 | 1,687 | 1,623 | 0 |
| 31 Dec 25 | 7,096 | 1,522 | 1,658 | 0 |
| 30 Sep 25 | 7,067 | 1,474 | 1,590 | 0 |
| 30 Jun 25 | 6,683 | 1,369 | 1,552 | 0 |
| 31 Mar 25 | 6,369 | 1,311 | 1,501 | 0 |
| 31 Dec 24 | 6,275 | 1,329 | 1,460 | 0 |
| 30 Sep 24 | 6,194 | 1,371 | 1,434 | 0 |
| 30 Jun 24 | 6,311 | 1,386 | 1,394 | 0 |
| 31 Mar 24 | 6,239 | 1,333 | 1,355 | 0 |
| 31 Dec 23 | 6,048 | 1,371 | 1,327 | 0 |
| 30 Sep 23 | 5,859 | 1,248 | 1,296 | 0 |
| 30 Jun 23 | 5,668 | 1,166 | 1,257 | 0 |
| 31 Mar 23 | 5,406 | 1,056 | 1,217 | 0 |
| 31 Dec 22 | 5,337 | 979 | 1,167 | 0 |
| 30 Sep 22 | 5,251 | 960 | 1,131 | 0 |
| 30 Jun 22 | 5,135 | 995 | 1,111 | 0 |
| 31 Mar 22 | 5,294 | 1,196 | 1,099 | 0 |
| 31 Dec 21 | 5,309 | 1,268 | 1,040 | 0 |
| 30 Sep 21 | 5,350 | 1,424 | 1,000 | 0 |
| 30 Jun 21 | 5,325 | 1,500 | 930 | 0 |
| 31 Mar 21 | 5,018 | 1,459 | 898 | 0 |
| 31 Dec 20 | 4,820 | 1,459 | 891 | 0 |
| 30 Sep 20 | 4,569 | 1,364 | 868 | 0 |
| 30 Jun 20 | 4,481 | 1,301 | 859 | 0 |
| 31 Mar 20 | 4,440 | 1,293 | 852 | 0 |
| 31 Dec 19 | 4,480 | 1,302 | 871 | 0 |
| 30 Sep 19 | 4,366 | 1,210 | 900 | 0 |
| 30 Jun 19 | 4,288 | 1,148 | 891 | 0 |
| 31 Mar 19 | 4,220 | 1,111 | 888 | 0 |
| 31 Dec 18 | 4,194 | 1,061 | 873 | 0 |
| 30 Sep 18 | 4,261 | 1,068 | 838 | 0 |
| 30 Jun 18 | 4,199 | 1,039 | 737 | 0 |
| 31 Mar 18 | 3,918 | 901 | 752 | 0 |
| 31 Dec 17 | 3,660 | 837 | 687 | 0 |
| 30 Sep 17 | 3,213 | 725 | 624 | 0 |
| 30 Jun 17 | 3,127 | 793 | 592 | 0 |
| 31 Mar 17 | 3,290 | 915 | 546 | 0 |
| 31 Dec 16 | 3,260 | 942 | 536 | 0 |
| 30 Sep 16 | 3,404 | 998 | 521 | 0 |
| 30 Jun 16 | 3,184 | 854 | 489 | 0 |
| 31 Mar 16 | 2,938 | 759 | 486 | 0 |
Kaliteli Kazançlar: ADVENZYMES yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: ADVENZYMES 'nin mevcut net kar marjları (21.6%) geçen yılın (20.6%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ADVENZYMES şirketinin kazancı son 5 yılda yılda 3.8% oranında arttı.
Büyüme Hızlandırma: ADVENZYMES 'un son bir yıldaki kazanç büyümesi ( 28.7% ) 5 yıllık ortalamasını (yıllık 3.8% ) aşıyor.
Kazançlar vs. Sektör: ADVENZYMES geçen yılki kazanç büyümesi ( 28.7% ) Chemicals sektörünün 10.1% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: ADVENZYMES 'nin Özsermaye Getirisi ( 10.3% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/24 08:42 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Advanced Enzyme Technologies Limited 4 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |